

Amendments To The Claims

1 – 41. (Previously canceled).

42. (Previously added) A method for inhibiting a humoral immune response comprising contacting T-cells with an antibody that binds specifically to a protein specifically recognized by monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048.

43. (Amended) A method for inhibiting a humoral immune response comprising contacting T-cells with an antibody that binds specifically to CD40CR, a 39 kD protein on helper T cell membranes, which binds to CD40 B-cell antigen and stimulates B-cell cycle entry, proliferation, and differentiation.

44. (Previously added) A method for inhibiting immunoglobulin production comprising contacting T-cells with an antibody that specifically binds to a protein specifically recognized by monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048.

45. (Amended) A method for inhibiting immunoglobulin production comprising contacting T-cells with an antibody that specifically binds to CD40CR, a 39 kD protein on helper T cell membranes, which binds to CD40 B-cell antigen and stimulates B-cell cycle entry, proliferation, and differentiation.

46. (Previously added) A method for inhibiting activation of B-cells comprising contacting T-cells with an antibody that specifically binds to a protein specifically recognized by monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048.

47. (Amended) A method for inhibiting activation of B-cells comprising contacting T-cells with an antibody that specifically binds to CD40CR, a 39 kD protein on

helper T cell membranes, which binds to CD40 B-cell antigen and stimulates B-cell cycle entry, proliferation, and differentiation.

48. (Amended) A method for inhibiting a humoral immune response in an animal comprising the step of administering to the animal in an amount effective to inhibit the humoral immune response, an antibody ~~or fragment thereof~~ that binds specifically to a protein specifically recognized by monoclonal antibody ~~5e8~~ MR1 produced by the hybridoma having ATCC Accession No. HB 11048.

49. (Amended) A method for inhibiting a humoral immune response in an animal comprising the step of administering to the animal, in an amount effective to inhibit the humoral immune response, an antibody ~~or fragment thereof~~ that specifically recognizes CD40CR, a 39 kD protein on helper T cell membranes, which binds to CD40 B-cell antigen and stimulates B-cell cycle entry, proliferation, and differentiation.

50. (Amended) A method for inhibiting immunoglobulin production in an animal comprising the step of administering to the animal, in an amount effective to inhibit immunoglobulin production, an antibody ~~or fragment thereof~~ that specifically binds to a protein specifically recognized by the hybridoma having ATCC Accession No. HB 11048.

51. (Amended) A method for inhibiting immunoglobulin production in an animal comprising the step of administering to the animal, in an amount effective to inhibit immunoglobulin production, an antibody ~~or fragment thereof~~ that specifically recognizes CD40CR, a 39 kD protein on helper T cell membranes, which binds to CD40 B-cell antigen and stimulates B-cell cycle entry, proliferation, and differentiation.

52. (Amended) A method for inhibiting activation of B-cells in an animal comprising administering to the animal, in an amount effective to inhibit activation of B-cells, an antibody ~~or fragment thereof~~ that specifically binds to a protein specifically recognized by monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048.

53. (Amended) A method for inhibiting activation of B-cells in an animal comprising administering to the animal, in an amount effective to inhibit activation of B-cells, an antibody ~~or fragment thereof~~ that specifically recognizes CD40CR, a 39 kD protein on helper T cell membranes, which binds to CD40 B-cell antigen and stimulates B-cell cycle entry, proliferation, and differentiation.

54. (Amended) The method of any one of Claims 42 through 53, wherein the antibody ~~or fragment thereof~~ is selected from the group consisting of monoclonal antibodies, chimeric antibodies, human antibodies, and fragments thereof that specifically bind to a protein specifically bound by the MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048.

55. (Amended) The method of any of Claims 42 through 53, wherein the antibody ~~or fragment thereof is conjugated to another~~ further comprises a moiety selected from the group consisting of an enzyme, a toxin, a growth factor, a lymphokine, an anti-proliferative agent, an alkylating agent, an anti-metabolite, an antibiotic, a vinca alkaloid, a platinum coordinated complex, a radioisotope, and a fluorescent compound, wherein the moiety is conjugated to the antibody.

56. (Amended) The method of any one of Claims 42 through 53, wherein the antibody ~~is conjugated to~~ further comprises a therapeutic agent, wherein the therapeutic agent is conjugated to the antibody.

57. (Previously added) The method of any of Claims 48 through 53, wherein the animal is a mammal.

58. (Previously added) The method of any of Claims 48 through 53, wherein the animal is a human.

59. (New) A method for inhibiting a humoral immune response comprising contacting T-cells with a composition comprising monoclonal antibody MR1 produced by the

hybridoma having ATCC Accession No. HB 11048, and fragments thereof that specifically bind to a protein specifically bound by the MR1 antibody.

60. (New) A method for inhibiting immunoglobulin production comprising contacting T-cells with a composition comprising monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048, and fragments thereof that specifically bind to a protein specifically bound by the MR1 antibody.

61. (New) A method for inhibiting activation of B-cells comprising contacting T-cells with a composition comprising monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048, and fragments thereof that specifically bind to a protein specifically bound by the MR1 antibody.

62. (New) A method for inhibiting a humoral immune response in an animal comprising the step of administering to the animal in an amount effective to inhibit the humoral immune response, a composition comprising monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048, and fragments thereof that specifically bind to a protein specifically bound by the MR1 antibody.

63. (New) A method for inhibiting immunoglobulin production in an animal comprising the step of administering to the animal, in an amount effective to inhibit immunoglobulin production, a composition comprising monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048, and fragments thereof that specifically bind to a protein specifically bound by the MR1 antibody.

64. (New) A method for inhibiting activation of B-cells in an animal comprising administering to the animal, in an amount effective to inhibit activation of B-cells, a composition comprising monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048, and fragments thereof that specifically bind to a protein specifically bound by the MR1 antibody.

65. (New) A method for inhibiting a humoral immune response comprising contacting T-cells with a human antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

66. (New) A method for inhibiting immunoglobulin production comprising contacting T-cells with a human antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

67. (New) A method for inhibiting activation of B-cells comprising contacting T-cells with a human antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

B1
68. (New) A method for inhibiting a humoral immune response in an animal comprising the step of administering to the animal in an amount effective to inhibit the humoral immune response, a composition comprising a human antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

69. (New) A method for inhibiting immunoglobulin production in an animal comprising the step of administering to the animal, in an amount effective to inhibit immunoglobulin production, a composition comprising a human antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

70. (New) A method for inhibiting activation of B-cells in an animal comprising administering to the animal, in an amount effective to inhibit activation of B-cells, a composition comprising a human antibody comprising a binding fragment of monoclonal

MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

71. (New) A method for inhibiting a humoral immune response comprising contacting T-cells with a chimeric antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

72. (New) A method for inhibiting immunoglobulin production comprising contacting T-cells with a chimeric antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

73. (New) A method for inhibiting activation of B-cells comprising contacting T-cells with a chimeric antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

74. (New) A method for inhibiting a humoral immune response in an animal comprising the step of administering to the animal in an amount effective to inhibit the humoral immune response, a composition comprising a human antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

75. (New) A method for inhibiting immunoglobulin production in an animal comprising the step of administering to the animal, in an amount effective to inhibit immunoglobulin production, a composition comprising a chimeric antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

76. (New) A method for inhibiting activation of B-cells in an animal comprising administering to the animal, in an amount effective to inhibit activation of B-cells, a composition comprising a chimeric antibody comprising a binding fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048, wherein the binding fragment specifically binds to a protein specifically bound by the MR1 antibody.

77. (New) A method for inhibiting a humoral immune response comprising contacting T-cells with an F(ab')₂ fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048.

78. (New) A method for inhibiting immunoglobulin production comprising contacting T-cells with an F(ab')₂ fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048.

79. (New) A method for inhibiting activation of B-cells comprising contacting T-cells with a chimeric antibody comprising an F(ab')₂ fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048.

80. (New) A method for inhibiting a humoral immune response in an animal comprising the step of administering to the animal in an amount effective to inhibit the humoral immune response, a composition comprising an F(ab')₂ fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048.

81. (New) A method for inhibiting immunoglobulin production in an animal comprising the step of administering to the animal, in an amount effective to inhibit immunoglobulin production, a composition comprising an F(ab')₂ fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048.

82. (New) A method for inhibiting activation of B-cells in an animal comprising administering to the animal, in an amount effective to inhibit activation of B-cells, a composition comprising an F(ab')₂ fragment of monoclonal MR1 antibody produced by the hybridoma having ATCC Accession No. HB 11048.